PharmaCyte Biotech (NASDAQ:PMCB) Posts Earnings Results

PharmaCyte Biotech (NASDAQ:PMCB) announced its earnings results on Monday. The company reported ($0.10) earnings per share for the quarter, Zacks reports.

PharmaCyte Biotech Price Performance

Shares of PMCB opened at $1.58 on Tuesday. PharmaCyte Biotech has a twelve month low of $1.39 and a twelve month high of $2.58. The company has a market capitalization of $10.85 million, a P/E ratio of 2.98 and a beta of -0.25. The firm has a 50 day moving average of $1.65 and a 200 day moving average of $1.70.

PharmaCyte Biotech Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.